iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function

Article metrics

  • 1029 Accesses

  • 1 Citations

  • A Correction to this article was published on 31 July 2019


Schizophrenia (SCZ) is a neurodevelopmental disorder. Thus, studying pathogenetic mechanisms underlying SCZ requires studying the development of brain cells. Cortical interneurons (cINs) are consistently observed to be abnormal in SCZ postmortem brains. These abnormalities may explain altered gamma oscillation and cognitive function in patients with SCZ. Of note, currently used antipsychotic drugs ameliorate psychosis, but they are not very effective in reversing cognitive deficits. Characterizing mechanisms of SCZ pathogenesis, especially related to cognitive deficits, may lead to improved treatments. We generated homogeneous populations of developing cINs from 15 healthy control (HC) iPSC lines and 15 SCZ iPSC lines. SCZ cINs, but not SCZ glutamatergic neurons, show dysregulated Oxidative Phosphorylation (OxPhos) related gene expression, accompanied by compromised mitochondrial function. The OxPhos deficit in cINs could be reversed by Alpha Lipoic Acid/Acetyl-L-Carnitine (ALA/ALC) but not by other chemicals previously identified as increasing mitochondrial function. The restoration of mitochondrial function by ALA/ALC was accompanied by a reversal of arborization deficits in SCZ cINs. OxPhos abnormality, even in the absence of any circuit environment with other neuronal subtypes, appears to be an intrinsic deficit in SCZ cINs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Change history

  • 31 July 2019

    A correction to this paper has been published and can be accessed via a link at the top of the paper.


  1. 1.

    Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17:1228–38.

  2. 2.

    Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660–9.

  3. 3.

    Harrison PJ. Postmortem studies in schizophrenia. Dialogues Clin Neurosci. 2000;2:349–57.

  4. 4.

    Jaffe AE. Postmortem human brain genomics in neuropsychiatric disorders–how far can we go? Curr Opin Neurobiol. 2016;36:107–11.

  5. 5.

    Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry. 2015;77:1031–40.

  6. 6.

    Arslan A. Imaging genetics of schizophrenia in the post-GWAS era. Prog Neuro-psychopharmacol Biol Psychiatry. 2018;80(Pt B):155–65.

  7. 7.

    Kotrla KJ, Weinberger DR. Brain imaging in schizophrenia. Ann Rev Med. 1995;46:113–22.

  8. 8.

    Kim SY, Cohen BM, Chen X, Lukas SE, Shinn AK, Yuksel AC, et al. Redox dysregulation in schizophrenia revealed by in vivo NAD + /NADH measurement. Schizophrenia Bull. 2017;43:197–204.

  9. 9.

    Du F, Cooper AJ, Thida T, Sehovic S, Lukas SE, Cohen BM, et al. In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy. JAMA Psychiatry. 2014;71:19–27.

  10. 10.

    Matigian NA, McCurdy RD, Feron F, Perry C, Smith H, Filippich C, et al. Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative? PLoS ONE. 2008;3:e2412.

  11. 11.

    Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide danish twin register. Biol Psychiatry. 2018;83:492–8.

  12. 12.

    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.

  13. 13.

    Forrest MP, Zhang H, Moy W, McGowan H, Leites C, Dionisio LE, et al. Open chromatin profiling in hiPSC-derived neurons prioritizes functional noncoding psychiatric risk variants and highlights neurodevelopmental loci. Cell Stem Cell. 2017;21:305–18 e308.

  14. 14.

    Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018;24:1579–89.

  15. 15.

    Srikanth P, Han K, Callahan DG, Makovkina E, Muratore CR, Lalli MA, et al. Genomic DISC1 disruption in hiPSCs alters Wnt signaling and neural cell fate. Cell Rep. 2015;12:1414–29.

  16. 16.

    Windrem MS, Osipovitch M, Liu Z, Bates J, Chandler-Militello D, Zou L, et al. Human iPSC glial mouse chimeras reveal glial contributions to schizophrenia. Cell Stem Cell. 2017;21:195–208 e196.

  17. 17.

    Barnes J, Salas F, Mokhtari R, Dolstra H, Pedrosa E, Lachman HM. Modeling the neuropsychiatric manifestations of Lowe syndrome using induced pluripotent stem cells: defective F-actin polymerization and WAVE-1 expression in neuronal cells. Mol Autism. 2018;9:44.

  18. 18.

    Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell. 2013;12:487–96.

  19. 19.

    Pak C, Danko T, Zhang Y, Aoto J, Anderson G, Maxeiner S, et al. Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell. 2015;17:316–28.

  20. 20.

    Stachowiak EK, Benson CA, Narla ST, Dimitri A, Chuye LEB, Dhiman S, et al. Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1. Transl Psychiatry. 2017;7:6.

  21. 21.

    Noh H, Shao ZC, Coyle JT, Chung SM. Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). Bba-Mol Basis Dis. 2017;1863:2382–7.

  22. 22.

    Benes FM. The GABA system in schizophrenia: cells, molecules and microcircuitry. Schizophr Res. 2015;167:1–3.

  23. 23.

    Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6:312–24.

  24. 24.

    Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35:57–67.

  25. 25.

    Volk DW, Lewis DA. Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia. Schizophrenia Bull. 2014;40:952–7.

  26. 26.

    Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008;165:1585–93.

  27. 27.

    Kim TG, Yao R, Monnell T, Cho JH, Vasudevan A, Koh A, et al. Efficient specification of interneurons from human pluripotent stem cells by dorsoventral and rostrocaudal modulation. Stem Cells. 2014;32:1789–804.

  28. 28.

    Ahn S, Kim TG, Kim KS, Chung S. Differentiation of human pluripotent stem cells into Medial Ganglionic Eminence vs. Caudal Ganglionic Eminence cells. Methods. 2016;101:103–12.

  29. 29.

    Lopez-Domenech G, Higgs NF, Vaccaro V, Ros H, Arancibia-Carcamo IL, MacAskill AF, et al. Loss of dendritic complexity precedes neurodegeneration in a mouse model with disrupted mitochondrial distribution in mature dendrites. Cell Rep. 2016;17:317–27.

  30. 30.

    Mendoza E, Miranda-Barrientos JA, Vazquez-Roque RA, Morales-Herrera E, Ruelas A, De la Rosa G, et al. In vivo mitochondrial inhibition alters corticostriatal synaptic function and the modulatory effects of neurotrophins. Neuroscience. 2014;280:156–70.

  31. 31.

    Tsuyama T, Tsubouchi A, Usui T, Imamura H, Uemura T. Mitochondrial dysfunction induces dendritic loss via eIF2alpha phosphorylation. J Cell Biol. 2017;216:815–34.

  32. 32.

    Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell. 2004;119:873–87.

  33. 33.

    Haak LL, Grimaldi M, Smaili SS, Russell JT. Mitochondria regulate Ca2+ wave initiation and inositol trisphosphate signal transduction in oligodendrocyte progenitors. J Neurochem. 2002;80:405–15.

  34. 34.

    Montalvo GB, Artalejo AR, Gilabert JA. ATP from subplasmalemmal mitochondria controls Ca2+ -dependent inactivation of CRAC channels. J Biol Chem. 2006;281:35616–23.

  35. 35.

    Vanden Berghe P, Kenyon JL, Smith TK. Mitochondrial Ca2 + uptake regulates the excitability of myenteric neurons. J Neurosci. 2002;22:6962–71.

  36. 36.

    Demaurex N, Poburko D, Frieden M. Regulation of plasma membrane calcium fluxes by mitochondria. Biochim et Biophys Acta. 2009;1787:1383–94.

  37. 37.

    Katsura K, Kristian T, Siesjo BK. Energy metabolism, ion homeostasis, and cell damage in the brain. Biochem Soc Trans. 1994;22:991–6.

  38. 38.

    Hiraoka M. Metabolic pathways for ion homeostasis and persistent Na(+) current. J Cardiovasc Electrophysiol. 2006;17:S124–S126.

  39. 39.

    Bergman O, Ben-Shachar D. Mitochondrial oxidative phosphorylation system (OXPHOS) deficits in schizophrenia: possible interactions with cellular processes. Can J Psychiatry. 2016;61:457–69.

  40. 40.

    Wallace DC. A Mitochondrial etiology of neuropsychiatric disorders. JAMA Psychiatry. 2017;74:863–4.

  41. 41.

    Cuperfain AB, Zhang ZL, Kennedy JL, Goncalves VF. The complex interaction of mitochondrial genetics and mitochondrial pathways in psychiatric disease. Mol Neuropsychiatry. 2018;4:52–69.

  42. 42.

    Devaraju P, Yu J, Eddins D, Mellado-Lagarde MM, Earls LR, Westmoreland JJ, et al. Haploinsufficiency of the 22q11.2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium. Mol Psychiatry. 2016;22:1313.

  43. 43.

    Inan M, Zhao M, Manuszak M, Karakaya C, Rajadhyaksha AM, Pickel VM, et al. Energy deficit in parvalbumin neurons leads to circuit dysfunction, impaired sensory gating and social disability. Neurobiol Dis. 2016;93:35–46.

  44. 44.

    Kim H, Kim HJ, Lee K, Kim JM, Kim HS, Kim JR, et al. alpha-Lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway. J Cell Mol Med. 2012;16:273–86.

  45. 45.

    Hiller S, DeKroon R, Xu LQ, Robinette J, Winnik W, Alzate O, et al. alpha-Lipoic acid protects mitochondrial enzymes and attenuates lipopolysaccharide-induced hypothermia in mice. Free Radical Bio Med. 2014;71:362–7.

  46. 46.

    Patel SP, Sullivan PG, Lyttle TS, Rabchevsky AG. Acetyl-L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury. J Neurochem. 2010;114:291–301.

  47. 47.

    Li X, Zhang C, Zhang X, Wang S, Meng Q, Wu S, et al. An acetyl-L-carnitine switch on mitochondrial dysfunction and rescue in the metabolomics study on aluminum oxide nanoparticles. Part Fibre Toxicol. 2016;13:4.

  48. 48.

    Shao Z, Noh H, Bin Kim W, Ni P, Nguyen C, Cote SE, et al. Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. Nat Neurosci. 2019;22:229–42.

  49. 49.

    liss LA, Sams MR, Deep-Soboslay A, Ren-Patterson R, Jaffe AE, Chenoweth JG, et al. Use of postmortem human dura mater and scalp for deriving human fibroblast cultures. PloS ONE. 2012;7:e45282.

  50. 50.

    Warren L, Ni Y, Wang J, Guo X. Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci Rep. 2012;2:657.

  51. 51.

    Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525–7.

  52. 52.

    Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013;29:1830–1.

  53. 53.

    Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.

  54. 54.

    Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–D361.

  55. 55.

    Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5:889–99.

  56. 56.

    Quiros PM, Mottis A, Auwerx J. Mitonuclear communication in homeostasis and stress. Nat Rev Mol Cell Biol. 2016;17:213–26.

  57. 57.

    Biswas G, Guha M, Avadhani NG. Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis. Gene. 2005;354:132–9.

  58. 58.

    Pellegrino MW, Nargund AM, Haynes CM. Signaling the mitochondrial unfolded protein response. Biochimica et Biophysica Acta. 2013;1833:410–6.

  59. 59.

    Cagin U, Enriquez JA. The complex crosstalk between mitochondria and the nucleus: What goes in between? Int J Biochem Cell Biol. 2015;63:10–15.

  60. 60.

    Herring AH. Applied longitudinal analysis, Vol. 23. 2nd edn. In: Garrett M. Fitzmaurice, Nan M. Laird, James H. Ware, (editors) John Wiley & Sons 2011; 2013. p. 940–1.

  61. 61.

    Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–74.

  62. 62.

    Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785–98.

  63. 63.

    Nehme R, Zuccaro E, Ghosh SD, Li C, Sherwood JL, Pietilainen O, et al. Combining NGN2 programming with developmental patterning generates human excitatory neurons with NMDAR-mediated synaptic transmission. Cell Rep. 2018;23:2509–23.

  64. 64.

    Van Haute L, Powell CA, Minczuk M. Dealing with an unconventional genetic code in mitochondria: the biogenesis and pathogenic defects of the 5-formylcytosine modification in mitochondrial tRNA(Met). Biomolecules. 2017;7:E24. pii

  65. 65.

    Trixl L, Amort T, Wille A, Zinni M, Ebner S, Hechenberger C, et al. RNA cytosine methyltransferase Nsun3 regulates embryonic stem cell differentiation by promoting mitochondrial activity. Cell Mol Life Sci. 2018;75:1483–97.

  66. 66.

    Korman SH, Kanazawa N, Abu-Libdeh B, Gutman A, Tsujino S. Hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome with evidence of mitochondrial dysfunction due to a novel SLC25A15 (ORNT1) gene mutation in a Palestinian family. J Neurol Sci. 2004;218:53–58.

  67. 67.

    Geiger J, Dalgaard LT. Interplay of mitochondrial metabolism and microRNAs. Cell Mol Life Sci. 2017;74:631–46.

  68. 68.

    Meister G. Argonaute proteins: functional insights and emerging roles. Nat Rev Genet. 2013;14:447–59.

  69. 69.

    Ogita K, Okuda H, Kitano M, Fujinami Y, Ozaki K, Yoneda Y. Localization of activator protein-1 complex with DNA binding activity in mitochondria of murine brain after in vivo treatment with kainate. J Neurosci. 2002;22:2561–70.

  70. 70.

    Ogita K, Fujinami Y, Kitano M, Yoneda Y. Transcription factor activator protein-1 expressed by kainate treatment can bind to the non-coding region of mitochondrial genome in murine hippocampus. J Neurosci Res. 2003;73:794–802.

  71. 71.

    Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxid Med Cell Longev. 2017;2017:6501046.

  72. 72.

    Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002;99:1870–5.

  73. 73.

    Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 2008;33:194–203.

  74. 74.

    Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta. 2009;1790:1149–60.

  75. 75.

    Afshordel S, Hagl S, Werner D, Rohner N, Kogel D, Bazan NG, et al. Omega-3 polyunsaturated fatty acids improve mitochondrial dysfunction in brain aging–impact of Bcl-2 and NPD-1 like metabolites. Prostaglandins Leukot Essent Fatty Acids. 2015;92:23–31.

  76. 76.

    Kitajka K, Puskas LG, Zvara A, Hackler L Jr., Barcelo-Coblijn G, et al. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci USA. 2002;99:2619–24.

  77. 77.

    Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci USA. 2004;101:10931–6.

  78. 78.

    Harbeby E, Jouin M, Alessandri JM, Lallemand MS, Linard A, Lavialle M, et al. n-3 PUFA status affects expression of genes involved in neuroenergetics differently in the fronto-parietal cortex compared to the CA1 area of the hippocampus: effect of rest and neuronal activation in the rat. Prostaglandins Leukot Essent Fatty Acids. 2012;86:211–20.

  79. 79.

    Schniertshauer D, Gebhard D, Bergemann J. Age-dependent loss of mitochondrial function in epithelial tissue can be reversed by coenzyme Q10. J Aging Res. 2018;2018:6354680.

  80. 80.

    Chokchaiwong S, Kuo YT, Lin SH, Hsu YC, Hsu SP, Liu YT, et al. Coenzyme Q10 serves to couple mitochondrial oxidative phosphorylation and fatty acid beta-oxidation, and attenuates NLRP3 inflammasome activation. Free Radic Res. 2018;52:1–11.

  81. 81.

    Martinez M, Ferrandiz ML, De Juan E, Miquel J. Age-related changes in glutathione and lipid peroxide content in mouse synaptic mitochondria: relationship to cytochrome c oxidase decline. Neurosci Lett. 1994;170:121–4.

  82. 82.

    Martinez Banaclocha M. N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson’s disease. Brain Res. 2000;859:173–5.

  83. 83.

    Navarro A, Bandez MJ, Lopez-Cepero JM, Gomez C, Boveris A. High doses of vitamin E improve mitochondrial dysfunction in rat hippocampus and frontal cortex upon aging. Am J Physiol Regul Integr Comp Physiol. 2011;300:R827–834.

  84. 84.

    Maurer I, Zierz S, Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res. 2001;48:125–36.

  85. 85.

    Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry. 2004;55:676–84.

  86. 86.

    Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241–53.

  87. 87.

    Roberts RC. Postmortem studies on mitochondria in schizophrenia. Schizophr Res. 2017;187:17–25.

  88. 88.

    Duncan LE, Holmans PA, Lee PH, O’Dushlaine CT, Kirby AW, Smoller JW, et al. Pathway analyses implicate glial cells in schizophrenia. PLoS ONE. 2014;9:e89441.

  89. 89.

    Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol. 2018;28:369–80.

  90. 90.

    Toker L, Mancarci BO, Tripathy S, Pavlidis P. Transcriptomic evidence for alterations in astrocytes and parvalbumin interneurons in subjects with bipolar disorder and schizophrenia. Biol Psychiatry. 2018;84:787–96.

  91. 91.

    Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878–93.

  92. 92.

    Do KQ, Cuenod M, Hensch TK. Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia. Schizophr Bull. 2015;41:835–46.

  93. 93.

    Handy DE, Loscalzo J. Redox regulation of mitochondrial function. Antioxid Redox Signal. 2012;16:1323–67.

  94. 94.

    Robicsek O, Ene HM, Karry R, Ytzhaki O, Asor E, McPhie D, et al. Isolated mitochondria transfer improves neuronal differentiation of schizophrenia-derived induced pluripotent stem cells and rescues deficits in a rat model of the disorder. Schizophr Bull. 2018;44:432–42.

  95. 95.

    Moraes CT. Mitochondrial disorders. Curr Opin Neurol. 1996;9:369–74.

  96. 96.

    Suomalainen A. Mitochondrial roles in disease: a box full of surprises. EMBO Mol Med. 2015;7:1245–7.

  97. 97.

    Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Delivery Rev. 2008;60:1561–7.

  98. 98.

    Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA. 2002;99:2356–61.

  99. 99.

    Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, et al. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2007;17:791–802.

  100. 100.

    Applegate MA, Humphries KM, Szweda LI. Reversible inhibition of alpha-ketoglutarate dehydrogenase by hydrogen peroxide: glutathionylation and protection of lipoic acid. Biochemistry. 2008;47:473–8.

  101. 101.

    Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Rad Biol Med. 1995;19:227–50.

  102. 102.

    Ou P, Tritschler HJ, Wolff SP. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochemical Pharmacol. 1995;50:123–6.

  103. 103.

    Rebouche CJ. Carnitine function and requirements during the life cycle. FASEB J. 1992;6:3379–86.

  104. 104.

    Costell M, Grisolia S. Effect of carnitine feeding on the levels of heart and skeletal muscle carnitine of elderly mice. FEBS Lett. 1993;315:43–46.

  105. 105.

    Gulcin I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006;78:803–11.

  106. 106.

    Robicsek O, Karry R, Petit I, Salman-Kesner N, Muller FJ, Klein E, et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol Psychiatry. 2013;18:1067–76.

  107. 107.

    Paulsen Bda S, de Moraes Maciel R, Galina A, Souza da Silveira M, dos Santos Souza C, Drummond H, et al. Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. Cell Transplant. 2012;21:1547–59.

  108. 108.

    Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K, et al. Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Mol Psychiatry. 2015;20:361–8.

  109. 109.

    Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.

  110. 110.

    Hjelm BE, Rollins B, Mamdani F, Lauterborn JC, Kirov G, Lynch G, et al. Evidence of mitochondrial dysfunction within the complex genetic etiology of schizophrenia. Mol Neuropsychiatry. 2015;1:201–19.

  111. 111.

    Corvin A, Sullivan PF. What next in schizophrenia genetics for the psychiatric genomics Consortium? Schizophr Bull. 2016;42:538–41.

Download references


This study was supported by MH107884 (S.C.) and NYSTEM C32607GG (S.C.). We thank Karen F. Berman, MD and Jose Apud, MD PhD at the National Institute of Mental Health for their contribution in providing patient samples.

Authors contributions

P.N., H.N., G.-H.P., Z.S. and S.C. designed the experiments. P.N., H.N., G.-H.P., Z.S., Y.G., J.M.P., S.Y., J.S.P., J.T.C., C.Y., W.H. and S.C. conducted experiments, collected data, and analyzed the data. P.N., W.H., and S.C. wrote the manuscript. D.R.W., R.E.S., B.M.C. and D.L.M. provided patient cell lines and reviewed data interpretation and manuscript contents. H.-Y.K. performed statistical analysis. S.C. supported this study financially.

Author information

Correspondence to Sangmi Chung.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading